# PBS Biotech

sells single-use Vertical-Wheel bioreactors (including a 15L system for cell-therapy scale-up) using a low-shear vertical impeller design documented in peer-reviewed research to predict maximum achievable cell density before oxygen-transfer becomes limiting for iPSC aggregate cultures.


Source: https://en.bioecon.ru/companies/pbs-biotech/
Updated: 2026-08-14

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $58.68M total funding (latest $17M in Jan 2025) | https://www.prnewswire.com/news-releases/pbs-biotech-expands-leadership-team-and-secures-17-million-in-growth-capital-to-accelerate-delivery-of-next-generation-cell-and-regenerative-therapies-302341410.html |
| Capacity | expanding capacity to support over $100M in annual revenue as of 2025 | https://www.prnewswire.com/news-releases/pbs-biotech-expands-leadership-team-and-secures-17-million-in-growth-capital-to-accelerate-delivery-of-next-generation-cell-and-regenerative-therapies-302341410.html |
| Certification | ISO 9001:2015 certified; products meet USP Class VI and/or ISO 10993 standards | https://pbsbiotech.com/company, https://pbsbiotech.com/pbs-15-bioreactors |
| Regulatory approval | products manufactured to meet cGMP standards, with software options for 21 CFR Part 11 compliance | https://pbsbiotech.com/products-for-cell-therapy, https://www.pbsbiotech.com/products-for-cell-therapy |
| Production site | 63,800 sq. ft. facility in Camarillo, California, USA | https://pbsbiotech.com/company |
| Headcount | approximately 104-105 employees as of 2026 | https://getlatka.com/companies/pbsbiotech.com |
| Revenue | $31.6M in 2025 [medium confidence] | https://getlatka.com/companies/pbsbiotech.com |

Independent sources: getlatka.com, prnewswire.com

## Technologies

- [High-cell-density culture systems](https://en.bioecon.ru/technology/high-cell-density-culture-systems/)